NEW YORK (GenomeWeb News) – Fluidigm has decided to the pull the plug on its proposed initial public offering “due to the historic instability in the market,” the firm said today.
 
The South San Francisco-based company had expected to offer 5.3 million shares of common stock at a price of between $14 and $16 per share. It had expected to raise net proceeds of between $70.8 million and $81.9 million from the offering, which was to fund sales and marketing initiatives, R&D activities, and facilities and manufacturing expansion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.